Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nimotuzumab - InnoMab

X
Drug Profile

Nimotuzumab - InnoMab

Alternative Names: BIOMAb EGFR; CIMAher; Cimaher; DE-766; h-R3; KI-0501; KI-0502; OSAG101; Taixinsheng; TheraCIM; TheraCIM hR3; Theraloc; VECTHIX

Latest Information Update: 17 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Center of Molecular Immunology; CIMYM
  • Developer Biocon Biopharmaceuticals; Biotech Pharmaceutical; Center of Molecular Immunology; CIMYM; Daiichi Sankyo Inc; Eurofarma; Gilead Sciences; Innogene Kalbiotech; InnoMab; Kuhnil Pharmaceutical Company; Laboratorios Pisa; Oncoscience
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Glioma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Anaplastic astrocytoma; Brain cancer; Glioblastoma; Glioma; Head and neck cancer; Nasopharyngeal cancer; Oesophageal cancer
  • Phase III Cervical cancer; Non-small cell lung cancer; Pancreatic cancer
  • Phase II/III Triple negative breast cancer
  • Phase II Colorectal cancer
  • No development reported Breast cancer; Gastric cancer; Polycystic kidney disease; Prostate cancer
  • Discontinued Brain metastases; Squamous cell cancer

Most Recent Events

  • 31 May 2024 Long term efficacy and adverse events data from a phase III trial in Head and neck cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 02 Apr 2024 Biotech Pharmaceutical plans a phase III trial for Colorectal cancer (Metastatic disease, Second-line therapy or greater, Combination therapy) (IV, Injection) (NCT06343116)
  • 27 Mar 2024 Biotech Pharmaceutical plans a phase III trial for Cervical cancer (Late-stage disease, Combination therapy) in unknown location (IV) (NCT06333821)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top